These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery.
    Author: Zou A, Chen Y, Huo M, Wang J, Zhang Y, Zhou J, Zhang Q.
    Journal: J Pharm Sci; 2013 Jan; 102(1):126-35. PubMed ID: 23073894.
    Abstract:
    Octreotide (OCT) was recently found to have a high binding affinity for the somatostatin receptor expressed on tumor cells. In this study, OCT-polyethylene glycol-stearic acid (OCT-Phe-PEG-A) was used as a targeting molecule for N-octyl-O, N-carboxymethyl chitosan (OCC) micelles loaded with doxorubicin (DOX). For in vivo fluorescence imaging, the fluorescent probe Cyanine 7 (Cy7) was successfully loaded into OCC micelles with or without OCT modification (Cy7-OCC, Cy7-OCC-OCT), and their physicochemical properties were compared with DOX-loaded micelles (DOX-OCC and DOX-OCC-OCT). All micelles were less than 120 nm with spherical shape and zeta potential of around -30 mV. Enhanced tumor-targeting capacity of OCC-OCT micelles was observed in BALB/c nude mice bearing MCF-7 cancer xenografts as compared with the OCC micelles. Moreover, pharmacodynamic studies demonstrated that DOX-OCC-OCT presented a strongest inhibition of tumor growth and lowest systemic toxicity compared with the DOX solution and DOX-OCC micelles. All the results indicated that OCC-OCT micelles might be a promising tumor-targeting carrier for cancer therapy.
    [Abstract] [Full Text] [Related] [New Search]